A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT ID: NCT06257875

Last Updated: 2025-10-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

156 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-23

Study Completion Date

2027-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult participants with moderate to severe UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed.

Lutikizumab is an investigational product being developed for the treatment of moderate to severe UC. Participants are placed in groups called treatment arms. Each group receives a different treatment. In the Induction Period, participants will be randomized into 1 of 3 arms receiving lutikizumab Dose 1, lutikizumab Dose 2, or adalimumab. In the Maintenance Period, participants who responded to lutikizumab will be randomized into 1 of 2 arms of lutikizumab maintenance and participants who responded to adalimumab will continue to receive adalimumab. All participants who did not achieve clinical response per modified Mayo Score at the end of the Induction period will receive lutikizumab. Around 200 adult participants with UC will be enrolled at approximately 200 sites worldwide.

During the 12 week Induction Period, participants will be randomized to receive intravenous (IV) and subcutaneous (SC) lutikizumab or SC adalimumab. At the 12 week mark, participants who are on lutikizumab who have responded to treatment will be re-randomized to receive SC lutikizumab at different intervals until Week 52. Participants who are on adalimumab who are responding to treatment will continue to receive adalimumab. Participants who do not respond to treatment will receive SC lutikizumab. Participants who complete the Week 52 visit and in whom therapeutic benefit to study drug is confirmed by the investigator may roll over into an optional, 52-week long-term extension (LTE).

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Induction Group 1

Participants will receive Dose 1 of IV lutikizumab at Baseline followed by SC lutikizumab throughout induction.

Group Type EXPERIMENTAL

Lutikizumab

Intervention Type DRUG

Subcutaneous (SC) Injection

Lutikizumab

Intervention Type DRUG

Intravenous (IV) Infusion

Induction Group 2

Participants will receive Dose 2 of IV lutikizumab at Baseline followed by SC lutikizumab throughout induction.

Group Type EXPERIMENTAL

Lutikizumab

Intervention Type DRUG

Subcutaneous (SC) Injection

Lutikizumab

Intervention Type DRUG

Intravenous (IV) Infusion

Induction Group 3

Participants will receive adalimumab per label throughout induction.

Group Type EXPERIMENTAL

Adalimumab

Intervention Type DRUG

SC Injection

Maintenance Group 1

Participants who responded to lutikizumab induction group 1 or 2 will be re-randomized. Participants in this group will receive SC lutikizumab throughout the maintenance period.

Group Type EXPERIMENTAL

Lutikizumab

Intervention Type DRUG

Subcutaneous (SC) Injection

Maintenance Group 2

Participants who responded to lutikizumab induction group 1 or 2 will be re-randomized. Participants in this group will receive SC lutikizumab throughout the maintenance period.

Group Type EXPERIMENTAL

Lutikizumab

Intervention Type DRUG

Subcutaneous (SC) Injection

Maintenance Adalimumab

Participants who respond to adalimumab induction group 3 will continue to receive adalimumab per label in the maintenance period.

Group Type EXPERIMENTAL

Adalimumab

Intervention Type DRUG

SC Injection

Maintenance Non-Responders

Participants who do not respond to study drug at the end of induction period will receive SC lutikizumab in the maintenance period.

Group Type EXPERIMENTAL

Lutikizumab

Intervention Type DRUG

Subcutaneous (SC) Injection

Optional Long-Term Extension (LTE)

Participants who complete the maintenance period, are willing/able to inject study drug at home, and in whom therapeutic benefit to study drug is confirmed by the investigator, may participate in the optional 52-week LTE.

Group Type EXPERIMENTAL

Lutikizumab

Intervention Type DRUG

Subcutaneous (SC) Injection

Adalimumab

Intervention Type DRUG

SC Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lutikizumab

Subcutaneous (SC) Injection

Intervention Type DRUG

Lutikizumab

Intravenous (IV) Infusion

Intervention Type DRUG

Adalimumab

SC Injection

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ABT-981 ABT-981 Humira

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participant has had a diagnosis of Ulcerative Colitis (UC) for at least 90 days prior to Baseline. Appropriate documentation of biopsy results consistent with the diagnosis of UC in the assessment of the investigator, must be available.
* Active UC with a Modified Mayo Score (mMS) of 5 to 9 points and Mayo Endoscopic Subscore (ESS) of 2 to 3 (confirmed by central review).
* Demonstrated inadequate response to, loss of response to, or intolerance to at least one of the following: oral aminosalicylates, corticosteroids, immunomodulators, and/or advanced therapies.

Exclusion Criteria

* Current diagnosis of Crohn's Disease (CD) or inflammatory bowel disease-unclassified.
* Extent of inflammatory disease limited to the rectum as assessed by screening endoscopy.
* Prior inadequate response, intolerance or loss of response to adalimumab (including biosimilars). Note: Participant may be enrolled if he/she discontinued adalimumab for reasons other than those listed above (e.g., loss of insurance) or he/she has been exposed to other advanced therapies, including anti-TNFs other than adalimumab.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

ABBVIE INC.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gastro SB /ID# 258331

Chula Vista, California, United States

Site Status

Southern California Res. Ctr. /ID# 258391

Coronado, California, United States

Site Status

Newport Huntington Medical Group /ID# 258371

Huntington Beach, California, United States

Site Status

Om Research LLC /ID# 261383

Lancaster, California, United States

Site Status

UC Irvine Health /ID# 259824

Orange, California, United States

Site Status

University of Colorado Hospital /ID# 258388

Aurora, Colorado, United States

Site Status

Research Associates of South Florida, LLC /ID# 259813

Coral Gables, Florida, United States

Site Status

University of Florida College of Medicine /ID# 260402

Gainesville, Florida, United States

Site Status

Auzmer Research /ID# 260940

Lakeland, Florida, United States

Site Status

Atlantic Medical Research /ID# 258507

Margate, Florida, United States

Site Status

Homestead Associates in Research /ID# 260392

Miami, Florida, United States

Site Status

University of Miami /ID# 258396

Miami, Florida, United States

Site Status

JD Medical Group, LLC /ID# 261235

Miami, Florida, United States

Site Status

Gastroenterology Group Naples /ID# 258346

Naples, Florida, United States

Site Status

AdventHealth Medical Group Blood & Marrow Transplant at Orlando /ID# 260945

Orlando, Florida, United States

Site Status

GCP Clinical Research, LLC /ID# 260401

Tampa, Florida, United States

Site Status

Atlanta Ctr. for Gastro /ID# 259275

Decatur, Georgia, United States

Site Status

Gastroenterology Associates of Central Georgia, LLC /ID# 258359

Macon, Georgia, United States

Site Status

Gastroenterology Consultants, P.C /ID# 258352

Roswell, Georgia, United States

Site Status

Northwestern Medicine - Northwestern Memorial Hospital /ID# 259592

Chicago, Illinois, United States

Site Status

University of Chicago Medical Center /ID# 258491

Chicago, Illinois, United States

Site Status

IU Health University Hospital /ID# 260398

Indianapolis, Indiana, United States

Site Status

Univ Kansas Med Ctr /ID# 258489

Kansas City, Kansas, United States

Site Status

Louisiana Research Center, LLC /ID# 258330

Shreveport, Louisiana, United States

Site Status

Massachusetts General Hospital /Id# 259817

Boston, Massachusetts, United States

Site Status

Clin Res Inst of Michigan, LLC /ID# 258386

Chesterfield, Michigan, United States

Site Status

Clin Res Inst of Michigan, LLC /ID# 259267

Chesterfield, Michigan, United States

Site Status

Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 258493

Wyoming, Michigan, United States

Site Status

Mayo Clinic - Rochester /ID# 258402

Rochester, Minnesota, United States

Site Status

Univ New Mexico /ID# 258490

Albuquerque, New Mexico, United States

Site Status

NY Scientific /ID# 260937

Brooklyn, New York, United States

Site Status

NYU Langone Long Island Clinical Research Associates /ID# 258504

Lake Success, New York, United States

Site Status

Weill Cornell Medicine/NYP /ID# 258953

New York, New York, United States

Site Status

Columbia University Medical Center /ID# 258496

New York, New York, United States

Site Status

Atrium Health /ID# 258506

Charlotte, North Carolina, United States

Site Status

DJL Clinical Research, PLLC /ID# 259465

Charlotte, North Carolina, United States

Site Status

Atrium Health Wake Forest Baptist Medical Center /ID# 260387

Winston-Salem, North Carolina, United States

Site Status

Plains Clinical Research Center, LLC /ID# 258502

Fargo, North Dakota, United States

Site Status

Digestive Disease Specialists /ID# 258499

Oklahoma City, Oklahoma, United States

Site Status

Digestive Health Associates of Texas (DHAT) Research Institute - Garland /ID# 258358

Garland, Texas, United States

Site Status

Baylor College of Medicine /ID# 258394

Houston, Texas, United States

Site Status

BioStar Clinical Research Group - Houston - Katy Freeway /ID# 261164

Houston, Texas, United States

Site Status

Clinical Associates in Research Therapeutics of America, LLC /ID# 258403

San Antonio, Texas, United States

Site Status

Southern Star Research Institute, LLC /ID# 258347

San Antonio, Texas, United States

Site Status

Tyler Research Institute, LLC /ID# 258383

Tyler, Texas, United States

Site Status

Texas Digestive Disease Consultants - Webster /ID# 258718

Webster, Texas, United States

Site Status

University Physicians and Surgeons Inc. /ID# 260399

Huntington, West Virginia, United States

Site Status

Wisconsin Center for Advanced Research /ID# 258949

Milwaukee, Wisconsin, United States

Site Status

Bankstown-Lidcombe Hospital /ID# 259089

Bankstown, New South Wales, Australia

Site Status

Lyell McEwin Hospital /ID# 260580

Elizabeth Vale, South Australia, Australia

Site Status

The Queen Elizabeth Hospital /ID# 259482

Woodville South, South Australia, Australia

Site Status

St Vincent's Hospital Melbourne /ID# 259473

Fitzroy Melbourne, Victoria, Australia

Site Status

Fiona Stanley Hospital /ID# 259480

Murdoch, Western Australia, Australia

Site Status

Universitaetsklinikum St. Poelten /ID# 258256

Sankt Pölten, Lower Austria, Austria

Site Status

Medizinische Universitaet Wien /ID# 258026

Vienna, Vienna, Austria

Site Status

Universite Libre de Bruxelles - Hopital Erasme /ID# 258214

Anderlecht, Brussels Capital, Belgium

Site Status

UZ Gent /ID# 258210

Ghent, Oost-Vlaanderen, Belgium

Site Status

Vitaz /Id# 258222

Sint-Niklaas, Oost-Vlaanderen, Belgium

Site Status

Universitair Ziekenhuis Leuven /ID# 258226

Leuven, Vlaams-Brabant, Belgium

Site Status

AZ Maria Middelares /ID# 258219

Ghent, , Belgium

Site Status

CHU de Liege /ID# 258212

Liège, , Belgium

Site Status

Hospital Tsaritsa Yoanna /ID# 258338

Sofiya, Sofia, Bulgaria

Site Status

Medical Center - Doverie /ID# 261936

Sofiya, Sofia, Bulgaria

Site Status

ACIBADEM City Clinic Diagnostic-Consultative Center /ID# 258339

Sofiya, Sofia, Bulgaria

Site Status

Umbal Kaspela /ID# 258336

Plovdiv, , Bulgaria

Site Status

2nd Mhat /ID# 258337

Sofia, , Bulgaria

Site Status

UMHAT Sveti Ivan Rilski /ID# 261417

Sofia, , Bulgaria

Site Status

UMHAT Multiprofile Hospital for Active Treatment Sveta Marina /ID# 258878

Varna, , Bulgaria

Site Status

Gastroenterology and Internal Medicine Research Institution /ID# 258765

Edmonton, Alberta, Canada

Site Status

Covenant Health /ID# 258799

Edmonton, Alberta, Canada

Site Status

Toronto Digestive Disease Associates /ID# 260460

Vaughan, Ontario, Canada

Site Status

Klinicki bolnicki centar Zagreb /ID# 258145

Zagreb, City of Zagreb, Croatia

Site Status

Poliklinika Solmed /ID# 258147

Zagreb, City of Zagreb, Croatia

Site Status

POLIKLINIKA BORZAN d.o.o. /ID# 258146

Osijek, County of Osijek-Baranja, Croatia

Site Status

Specialty Hospital Medico /ID# 258169

Rijeka, Primorje-Gorski Kotar County, Croatia

Site Status

Klinicki Bolnicki Centar (KBC) Split /ID# 258153

Split, Split-Dalmatia County, Croatia

Site Status

West Tallinn Central Hospital /ID# 262035

Tallinn, Harju, Estonia

Site Status

Medicum /ID# 268320

Tallinn, Harju, Estonia

Site Status

Parnu Hospital /ID# 261783

Pärnu, , Estonia

Site Status

Tartu University Hospital /ID# 261782

Tartu, , Estonia

Site Status

Chu de Nice-Hopital L'Archet Ii /Id# 258041

Nice, Alpes-Maritimes, France

Site Status

CHU Toulouse - Hopital Rangueil /ID# 258044

Toulouse, Haute-Garonne, France

Site Status

Hopitaux Universitaires Henri Mondor - Hopital Henri Mondor /ID# 258555

Créteil, Paris, France

Site Status

Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 258042

Nantes, Pays de la Loire Region, France

Site Status

Centre Hospitalier Universitaire de Saint Etienne - Hopital Nord /ID# 258040

St-Priest-en-Jarez, Pays de la Loire Region, France

Site Status

Universitaetsklinikum Ulm /ID# 258616

Ulm, Baden-Wurttemberg, Germany

Site Status

Klinikum rechts der Isar /ID# 260228

Munich, Bavaria, Germany

Site Status

St. Marien- und St. Annastiftskrankenhaus /ID# 264691

Ludwigshafen am Rhein, Rhineland-Palatinate, Germany

Site Status

Eugastro /ID# 260229

Leipzig, Saxony, Germany

Site Status

Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 258614

Kiel, Schleswig-Holstein, Germany

Site Status

Universitaetsklinikum Hamburg-Eppendorf /ID# 258617

Hamburg, , Germany

Site Status

General Hospital of Chest Diseases of Athens SOTIRIA /ID# 257831

Athens, Attica, Greece

Site Status

University General Hospital of Heraklion PA.G.N.I /ID# 257832

Heraklion, Crete, Greece

Site Status

General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 257829

Athens, , Greece

Site Status

General Hospital of Thessaloniki Hippokrateio /ID# 260810

Thessaloniki, , Greece

Site Status

Clinfan /ID# 258094

Szekszárd, Tolna County, Hungary

Site Status

Clinexpert Kft /ID# 258449

Budapest, , Hungary

Site Status

Synexus Hungary Clinical Research Centre - Budapest /ID# 258915

Budapest, , Hungary

Site Status

Semmelweis Egyetem /ID# 258527

Budapest, , Hungary

Site Status

Szegedi Tudományegyetem /ID# 258095

Szeged, , Hungary

Site Status

St Vincents University Hospital /ID# 261560

Elm Park, Dublin, Ireland

Site Status

Beaumont Hospital /ID# 261561

Dublin, , Ireland

Site Status

Yitzhak Shamir Medical Center /ID# 258533

Ẕerifin, Central District, Israel

Site Status

Shaare Zedek Medical Center /ID# 258529

Jerusalem, Jerusalem, Israel

Site Status

Soroka University Medical Center /ID# 258530

Beersheba, Southern District, Israel

Site Status

The Chaim Sheba Medical Center /ID# 258532

Ramat Gan, Tel Aviv, Israel

Site Status

Tel Aviv Sourasky Medical Center /ID# 258528

Tel Aviv, Tel Aviv, Israel

Site Status

Rabin Medical Center /ID# 258531

Petah Tikva, , Israel

Site Status

Azienda Ospedaliero Universitaria di Cagliari - P.O. Duilio Casula /ID# 258455

Monserrato, Cagliari, Italy

Site Status

Azienda Ospedaliera San Camillo Forlanini /ID# 258453

Rome, Roma, Italy

Site Status

Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 258452

Rome, Roma, Italy

Site Status

IRCCS Ospedale Sacro Cuore Don Calabria /ID# 258456

Negrar, Verona, Italy

Site Status

Gamagori City Hospital /ID# 260682

Gamagori-shi, Aichi-ken, Japan

Site Status

Aichi Medical University Hospital /ID# 258867

Nagakute, Aichi-ken, Japan

Site Status

Tsujinaka Hospital - Kashiwanoha /ID# 258548

Kashiwa-shi, Chiba, Japan

Site Status

Juntendo University Urayasu Hospital /ID# 259582

Urayasu-shi, Chiba, Japan

Site Status

Kitakyushu Municipal Medical Center /ID# 259600

Kitakyushu-shi, Fukuoka, Japan

Site Status

Fukushima Medical University Hospital /ID# 259591

Fukushima, Fukushima, Japan

Site Status

Gifu University Hospital /ID# 259572

Gifu, Gifu, Japan

Site Status

Ogaki Municipal Hospital /ID# 259905

Ogaki-shi, Gifu, Japan

Site Status

National Hospital Organization Fukuyama Medical Center /ID# 258861

Fukuyama-shi, Hiroshima, Japan

Site Status

Aoyama Clinic /ID# 259587

Kobe, Hyōgo, Japan

Site Status

Hyogo Medical University Hospital /ID# 258827

Nishinomiya-shi, Hyōgo, Japan

Site Status

Sameshima Hospital /ID# 259589

Kagoshima, Kagoshima-ken, Japan

Site Status

Kagoshima IBD Gastroenterology Clinic /ID# 259603

Kagoshima, Kagoshima-ken, Japan

Site Status

Sai Gastroenterology and Proctology Clinic /ID# 260832

Fujidera-shi, Osaka, Japan

Site Status

Kinshukai Infusion Clinic /ID# 259588

Osaka, Osaka, Japan

Site Status

Saga University Hospital /ID# 259625

Saga, Saga-ken, Japan

Site Status

Tokitokai Tokito clinic /ID# 259036

Saitama-shi, Saitama, Japan

Site Status

Hamamatsu University Hospital /ID# 259580

Hamamatsu, Shizuoka, Japan

Site Status

NHO Shizuoka Medical Center /ID# 259033

Sunto-gun, Shizuoka, Japan

Site Status

Institute of Science Tokyo Hospital /ID# 259003

Bunkyo-ku, Tokyo, Japan

Site Status

Tokai University Hachioji Hospital /ID# 258897

Hachioji-shi, Tokyo, Japan

Site Status

Kyorin University Hospital /ID# 259843

Mitaka-shi, Tokyo, Japan

Site Status

Center hospital of the National Center for Global Health and Medicine /ID# 259598

Shinjuku-ku, Tokyo, Japan

Site Status

Toyama Prefectural Central Hospital /ID# 259499

Toyama, Toyama, Japan

Site Status

SIA Polana-D /ID# 262932

Daugavpils, , Latvia

Site Status

Liepaja Regional Hospital /ID# 261484

Liepāja, , Latvia

Site Status

Pauls Stradins Clinical University Hospital /ID# 261483

Riga, , Latvia

Site Status

Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 261486

Kaunas, , Lithuania

Site Status

Panevezys Republican Hospital /ID# 261780

Panevezys, , Lithuania

Site Status

Vilnius University Hospital Santaros Klinikos /ID# 261487

Vilnius, , Lithuania

Site Status

Dunedin Hospital /ID# 258584

Otago, Otago, New Zealand

Site Status

Waikato Hospital /ID# 258607

Hamilton, Waikato Region, New Zealand

Site Status

Hutt Hospital /ID# 258608

Lower Hutt, Wellington Region, New Zealand

Site Status

Akershus Universitetssykehus /ID# 261586

Nordbyhagen, Akershus, Norway

Site Status

Universitetssykehuset I Nord-Norge /ID# 261649

Tromsø, Troms, Norway

Site Status

Gastromed Sp. z o.o /ID# 258310

Torun, Kuyavian-Pomeranian Voivodeship, Poland

Site Status

Centrum Medyczne Melita Medical /ID# 258379

Wroclaw, Lower Silesian Voivodeship, Poland

Site Status

Medrise Sp. z o.o. /ID# 258561

Lublin, Lublin Voivodeship, Poland

Site Status

Centrum Medyczne Lukamed Sp. z o.o. /ID# 258457

Chojnice, Pomeranian Voivodeship, Poland

Site Status

H-T Centrum Medyczne Endoterapia /ID# 258540

Tychy, Silesian Voivodeship, Poland

Site Status

Twoja Przychodnia SCM /ID# 259280

Szczecin, West Pomeranian Voivodeship, Poland

Site Status

Centrum Opieki Zdrowotnej Orkan-Med Stec-Michalska Sp. j. /ID# 258842

Ksawerów, Łódź Voivodeship, Poland

Site Status

Clinical Research Investigator Group, LLC /ID# 260647

Bayamón, , Puerto Rico

Site Status

Caribbean Medical Research Center /ID# 268395

San Juan, , Puerto Rico

Site Status

School of Medicine University of Puerto Rico-Medical Science Campus /ID# 258508

San Juan, , Puerto Rico

Site Status

Clinical Hosp Center Zvezdara /ID# 257766

Belgrade, Beograd, Serbia

Site Status

University Clinical Center Serbia /ID# 257764

Belgrade, Beograd, Serbia

Site Status

Clinical Hospital Center Dr Dragisa Misovic - Dedinje /ID# 257768

Belgrade, Beograd, Serbia

Site Status

Clin Hosp Ctr Bezanijska Kosa /ID# 257765

Belgrade, Beograd, Serbia

Site Status

General Hospital Leskovac /ID# 257767

Leskovac, Jablanicki Okrug, Serbia

Site Status

University Clinical Center Vojvodina /ID# 257763

Novi Sad, , Serbia

Site Status

General Hospital Celje /ID# 261482

Celje, , Slovenia

Site Status

Univ Medical Ctr Ljubljana /ID# 261474

Ljubljana, , Slovenia

Site Status

Splosna bolnisnica Murska Sobota /ID# 262486

Murska Sobota, , Slovenia

Site Status

Clinresco Centers /ID# 258431

Johannesburg, Gauteng, South Africa

Site Status

Johese Clinical Research Midstream /ID# 260195

Pretoria, Gauteng, South Africa

Site Status

Private Practice Dr MN Rajabally /ID# 260671

Cape Town, Western Cape, South Africa

Site Status

Spoke Research Inc /ID# 258432

CAPE TOWN Milnerton, Western Cape, South Africa

Site Status

Inje University Haeundae Hospital /ID# 258822

Busan, Busan Gwang Yeogsi, South Korea

Site Status

Dong-A University Medical Center /ID# 258423

Busan, Busan Gwang Yeogsi, South Korea

Site Status

The Catholic University of Korea, Daejeon St. Mary's Hospital /ID# 258424

Daejeon, Daejeon Gwang Yeogsi, South Korea

Site Status

Kangbuk Samsung Hospital /ID# 258416

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Samsung Medical Center /ID# 258420

Seoul, Seoul Teugbyeolsi, South Korea

Site Status

Yonsei University Health System Severance Hospital /ID# 258422

Seoul, , South Korea

Site Status

Complejo Hospitalario Universitario de Santiago (CHUS) /ID# 259114

Santiago de Compostela, A Coruna, Spain

Site Status

Hospital Universitario de Navarra /ID# 258173

Pamplona, Navarre, Spain

Site Status

Hospital Universitario La Paz /ID# 258172

Madrid, , Spain

Site Status

Hospital Universitario Virgen Macarena /ID# 258175

Seville, , Spain

Site Status

Inselspital, Universitaetsspital Bern /ID# 260106

Bern, , Switzerland

Site Status

Intesto /ID# 260114

Bern, , Switzerland

Site Status

National Taiwan University Hospital /ID# 258476

Taipei City, Taipei, Taiwan

Site Status

National Taiwan University Hospital - Hsinchu branch /ID# 259422

Hsinchu, , Taiwan

Site Status

China Medical University Hospital /ID# 258478

Taichung, , Taiwan

Site Status

Linkou Chang Gung Memorial Hospital /ID# 258724

Taoyuan, , Taiwan

Site Status

Addenbrookes Hospital /ID# 258744

Cambridge, Cambridgeshire, United Kingdom

Site Status

Gartnavel General Hospital /ID# 258741

Glasgow, Glasgow City, United Kingdom

Site Status

Dup_Guys and St Thomas NHS Foundation Trust - Guy's Hospital /ID# 258730

London, Greater London, United Kingdom

Site Status

Oxford University Hospitals NHS Foundation Trust /ID# 258745

Oxford, Oxfordshire, United Kingdom

Site Status

Barts Health NHS Trust /ID# 258600

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Belgium Bulgaria Canada Croatia Estonia France Germany Greece Hungary Ireland Israel Italy Japan Latvia Lithuania New Zealand Norway Poland Puerto Rico Serbia Slovenia South Africa South Korea Spain Switzerland Taiwan United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023-505678-14-00

Identifier Type: OTHER

Identifier Source: secondary_id

M23-703

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Rituximab in Active Ulcerative Colitis
NCT00261118 COMPLETED PHASE2/PHASE3